{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:13:14Z","timestamp":1783750394936,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Elterninitiative krebskranker Kinder e.V."},{"name":"Tigerauge: Initiative Kinderhospitz Nordbayern e.V."},{"name":"Sonnenstrahl e.V. Dresden, F\u00f6rderkreis f\u00fcr krebskranke Kinder und Jugendliche"},{"DOI":"10.13039\/501100001652","name":"Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001652","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40262-026-01644-2","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:40:02Z","timestamp":1779172802000},"page":"1013-1026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8024-2839","authenticated-orcid":false,"given":"Phyllis","family":"Lensker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-9601","authenticated-orcid":false,"given":"Andrea","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2125-9084","authenticated-orcid":false,"given":"Thomas","family":"Zerjatke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6741-0608","authenticated-orcid":false,"given":"Ingo","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0334-7478","authenticated-orcid":false,"given":"Martin F.","family":"Fromm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-9212","authenticated-orcid":false,"given":"Frank","family":"D\u00f6rje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-8838","authenticated-orcid":false,"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4852-7157","authenticated-orcid":false,"given":"Manfred","family":"Rauh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2524-1199","authenticated-orcid":false,"given":"Ingmar","family":"Glauche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-1676","authenticated-orcid":false,"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"1644_CR1","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sj\u00f6berg J, et al. Success story of targeted therapy in chronic myeloid leukemia: A population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514\u201320.","journal-title":"J Clin Oncol"},{"key":"1644_CR2","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","volume":"32","author":"M Suttorp","year":"2018","unstructured":"Suttorp M, Schulze P, Glauche I, G\u00f6hring G, von Neuhoff N, Metzler M, et al. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial. Leukemia. 2018;32:1657\u201369.","journal-title":"Leukemia"},{"key":"1644_CR3","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Sau\u00dfele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398\u2013406.","journal-title":"Leukemia"},{"key":"1644_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"1644_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11:84.","journal-title":"J Hematol Oncol"},{"key":"1644_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7:345\u201356.","journal-title":"Nat Rev Cancer"},{"key":"1644_CR7","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","volume":"41","author":"M Garc\u00eda-Ferrer","year":"2019","unstructured":"Garc\u00eda-Ferrer M, Wojnicz A, Mej\u00eda G, Koller D, Zubiaur P, Abad-Santos F. Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis. Clin Ther. 2019;41:2558-70.e7.","journal-title":"Clin Ther"},{"key":"1644_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/FTD.0000000000000771","volume":"42","author":"L Smy","year":"2020","unstructured":"Smy L, Sadler AJ, McMillin GA. Evaluation of imatinib concentrations in samples submitted for BCR-ABL1 or imatinib testing-evidence to support therapeutic drug monitoring for dose optimization? Ther Drug Monit. 2020;42:559\u201364.","journal-title":"Ther Drug Monit"},{"key":"1644_CR9","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s00280-014-2599-1","volume":"74","author":"V Gotta","year":"2014","unstructured":"Gotta V, Widmer N, Decosterd LA, Chalandon Y, Heim D, Gregor M, et al. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemother Pharmacol. 2014;74:1307\u201319.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1644_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","volume":"157","author":"WA Clarke","year":"2021","unstructured":"Clarke WA, Chatelut E, Fotoohi AK, Larson RA, Martin JH, Mathijssen RHJ, et al. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur J Cancer. 2021;157:428\u201340.","journal-title":"Eur J Cancer"},{"key":"1644_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1329220","volume":"15","author":"H Yan","year":"2024","unstructured":"Yan H, Wang P, Yang F, Cheng W, Chen C, Zhai B, et al. Anticancer therapy-induced adverse drug reactions in children and preventive and control measures. Front Pharmacol. 2024;15:1329220.","journal-title":"Front Pharmacol"},{"key":"1644_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejca.2021.09.014","volume":"164","author":"S Barnett","year":"2022","unstructured":"Barnett S, Hellmann F, Parke E, Makin G, Tweddle DA, Osborne C, et al. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. Eur J Cancer. 2022;164:127\u201336.","journal-title":"Eur J Cancer"},{"key":"1644_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.815040","volume":"11","author":"S Barnett","year":"2021","unstructured":"Barnett S, Holden V, Campbell-Hewson Q, Veal GJ. Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations. Front Oncol. 2021;11:815040.","journal-title":"Front Oncol"},{"key":"1644_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41375-025-02543-4","volume":"39","author":"F Millot","year":"2025","unstructured":"Millot F, Ampatzidou M, Moulik NR, Tewari S, Elhaddad A, Hammad M, et al. Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations. Leukemia. 2025;39:779\u201391.","journal-title":"Leukemia"},{"key":"1644_CR15","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/bjh.20047","volume":"206","author":"M Suttorp","year":"2025","unstructured":"Suttorp M, Sembill S, Lensker P, Hildebrand V, Schirmer E, Karow A, et al. Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: data from a real-world setting. Br J Haematol. 2025;206:1397\u2013405.","journal-title":"Br J Haematol"},{"key":"1644_CR16","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1158\/1078-0432.CCR-24-4325","volume":"31","author":"KM Wessel","year":"2025","unstructured":"Wessel KM, Drezner N, Shord SS, Shah M, Theoret MR, Donoghue M. Dosage optimization of pediatric oncology products: our patients deserve better. Clin Cancer Res. 2025;31:2552\u20135.","journal-title":"Clin Cancer Res"},{"key":"1644_CR17","unstructured":"Summary of Product Characteristics (SmPC) Glivec\u00ae. https:\/\/www.fachinfo.de\/fi\/pdf\/008242\/glivec-r-filmtabletten. 2023. Accessed 13 Aug 2025."},{"key":"1644_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01672","volume":"10","author":"J Adiwidjaja","year":"2019","unstructured":"Adiwidjaja J, Boddy AV, McLachlan AJ. Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimens for imatinib and potential drug interactions in paediatrics. Front Pharmacol. 2019;10:1672.","journal-title":"Front Pharmacol"},{"key":"1644_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17512433.2018.1398644","volume":"11","author":"M Suttorp","year":"2018","unstructured":"Suttorp M, Bornh\u00e4user M, Metzler M, Millot F, Schleyer E. Pharmacology and pharmacokinetics of imatinib in pediatric patients. Expert Rev Clin Pharmacol. 2018;11:219\u201331.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1644_CR20","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"1644_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1570-0232(03)00206-X","volume":"791","author":"RA Parise","year":"2003","unstructured":"Parise RA, Ramanathan RK, Hayes MJ, Egorin MJ. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791:39\u201344.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1644_CR22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/bmc.1247","volume":"23","author":"J Klawitter","year":"2009","unstructured":"Klawitter J, Zhang YL, Klawitter J, Anderson N, Serkova NJ, Christians U. Development and validation of a sensitive assay for the quantification of imatinib using LC\/LC-MS\/MS in human whole blood and cell culture. Biomed Chromatogr. 2009;23:1251\u20138.","journal-title":"Biomed Chromatogr"},{"key":"1644_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","volume":"63","author":"D Menon-Andersen","year":"2009","unstructured":"Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, et al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009;63:229\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1644_CR24","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","volume":"14","author":"A Petain","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res. 2008;14:7102\u20139.","journal-title":"Clin Cancer Res"},{"key":"1644_CR25","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1200\/JCO.20.03088","volume":"39","author":"P D\u00fcrr","year":"2021","unstructured":"D\u00fcrr P, Schlichtig K, Kelz C, Deutsch B, Maas R, Eckart MJ, et al. The randomized AMBORA trial: impact of pharmacological\/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents. J Clin Oncol. 2021;39:1983\u201394.","journal-title":"J Clin Oncol"},{"key":"1644_CR26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1200\/OP.23.00694","volume":"20","author":"L Cuba","year":"2024","unstructured":"Cuba L, D\u00fcrr P, Gessner K, H\u00e4cker B, Fietkau R, Siebler J, et al. A hybrid type III effectiveness-implementation trial to optimize medication safety with oral antitumor therapy in real-world: the AMBORA Competence and Consultation Center. JCO Oncol Pract. 2024;20:1219\u201330.","journal-title":"JCO Oncol Pract"},{"key":"1644_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0315077","volume":"19","author":"P Lensker","year":"2024","unstructured":"Lensker P, Cuba L, Gessner K, Fromm MF, D\u00f6rje F, Metzler M. Medication safety with oral antitumour therapeutics in paediatrics (youngAMBORA): a mixed-methods approach towards a tailored care program. PLoS ONE. 2024;19:e0315077.","journal-title":"PLoS ONE"},{"key":"1644_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/11596990-000000000-00000","volume":"51","author":"V Gotta","year":"2012","unstructured":"Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, et al. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012;51:187\u2013201.","journal-title":"Clin Pharmacokinet"},{"key":"1644_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020119","volume":"14","author":"RAG van Eerden","year":"2021","unstructured":"van Eerden RAG, Oomen-de Hoop E, Noordam A, Mathijssen RHJ, Koolen SLW. Feasibility of extrapolating randomly taken plasma samples to trough levels for therapeutic drug monitoring purposes of small molecule kinase inhibitors. Pharmaceuticals Basel. 2021;14:119.","journal-title":"Pharmaceuticals Basel"},{"key":"1644_CR30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1634\/theoncologist.2015-0405","volume":"21","author":"JA Greer","year":"2016","unstructured":"Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21:354\u201376.","journal-title":"Oncologist"},{"key":"1644_CR31","first-page":"17","volume":"40","author":"JM Kahn","year":"2023","unstructured":"Kahn JM, Stevenson K, Beauchemin M, Koch VB, Cole PD, Welch JJG, et al. Oral mercaptopurine adherence in pediatric acute lymphoblastic leukemia: a survey study from the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. J Pediatr Hematol Oncol Nurs. 2023;40:17\u201323.","journal-title":"J Pediatr Hematol Oncol Nurs."},{"key":"1644_CR32","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on Imatinib. J Clin Oncol. 2010;28:2381\u20138.","journal-title":"J Clin Oncol"},{"key":"1644_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010316","volume":"15","author":"C Bandiera","year":"2023","unstructured":"Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, et al. Adherence to the CDK 4\/6 inhibitor Palbociclib and omission of dose management supported by pharmacometric modelling as part of the OpTAT study. Cancers. 2023;15:316.","journal-title":"Cancers"},{"key":"1644_CR34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/JU.0000000000003081","volume":"209","author":"CS Higano","year":"2023","unstructured":"Higano CS, Hafron J. Adherence with oral anticancer therapies: clinical trial vs real-world experiences with a focus on prostate cancer. J Urol. 2023;209:485\u201393.","journal-title":"J Urol"},{"key":"1644_CR35","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/cancers16122193","volume":"16","author":"A Ravix","year":"2024","unstructured":"Ravix A, Bandiera C, Cardoso E, Lata-Pedreira A, Chtioui H, Decosterd LA, et al. Population pharmacokinetics of trametinib and impact of nonadherence on drug exposure in oncology patients as part of the optimising oral targeted anticancer therapies study. Cancers. 2024;16:2193.","journal-title":"Cancers"},{"key":"1644_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1146108","volume":"13","author":"F Cheng","year":"2023","unstructured":"Cheng F, Li Q, Cui Z, Hong M, Li W, Zhang Y. Dose optimization strategy of the tyrosine kinase inhibitors Imatinib, Dasatinib, and Nilotinib for chronic myeloid leukemia: from clinical trials to real-life settings. Front Oncol. 2023;13:1146108.","journal-title":"Front Oncol"},{"key":"1644_CR37","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375\u201383.","journal-title":"Lancet Haematol"},{"key":"1644_CR38","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjh.13453","volume":"170","author":"F Giona","year":"2015","unstructured":"Giona F, Putti MC, Micalizzi C, Menna G, Moleti ML, Santoro N, et al. Long-term results of high-dose Imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br J Haematol. 2015;170:398\u2013407.","journal-title":"Br J Haematol"},{"key":"1644_CR39","doi-asserted-by":"publisher","first-page":"18199","DOI":"10.1038\/s41598-023-45364-0","volume":"13","author":"C Volz","year":"2023","unstructured":"Volz C, Zerjatke T, Gottschalk A, Semper S, Suttorp M, Glauche I, et al. Continuous therapy response references for BCR:ABL1 monitoring in pediatric chronic myeloid leukemia. Sci Rep. 2023;13:18199.","journal-title":"Sci Rep"},{"key":"1644_CR40","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","volume":"104","author":"MA Champagne","year":"2004","unstructured":"Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children\u2019s Oncology Group phase 1 study. Blood. 2004;104:2655\u201360.","journal-title":"Blood"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01644-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01644-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01644-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:36:57Z","timestamp":1783748217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01644-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1644"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01644-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: The author MFF has received consultancy fees and lecture fees from Boehringer Ingelheim. He has received third-party funds for research projects at his institution by Boehringer Ingelheim and Heidelberg Pharma Research GmbH. The author MM has received consultancy fees and research funding from Novartis, and consultancy fees from Bristol Myers Squibb (BMS). PL, AG, TZ, IR, FD, MS, MR, and IG have no relevant financial or non-financial interests to disclose. MFF and MM have no relevant non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analyses were performed by Phyllis Lensker, Andrea Gottschalk, and Markus Metzler. The first draft of the manuscript was written by Phyllis Lensker and Andrea Gottschalk, and all authors commented on this and the subsequent versions of the manuscript. All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The prospective CML-PAED-II study was conducted in accordance with the Declaration of Helsinki, approved by the institutional ethics boards (EK282 122006 and EK 236_18 B) and registered ad EUDRACT (2007-001339-69) and Clinical-Trials.gov (NCT00445822).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from the children and\/or their legal guardians.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Consent for publication was not applicable for this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets used in this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statements"}},{"value":"The R-code for the statistical analysis is available from the authors upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}